Oprettet i 2006 (France), I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome egen 2757 søstermærker og 17478 konkurrerende mærker. Mærket I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome er ejet af SANOFI, et selskab noteret i Paris. ISIN, virksomhedens internationale værdipapiridentifikationsnummer, er FR0000120578. I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome's sektor er Lægemiddelproducenter.

I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome er et mærke tilhørende SANOFI (SAN) Nyheder

International depositum : 2006 Erhvervssektor Lægemiddelproducenter

Alle nyheder Marketscreener-logo
SANOFI (I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome)

loader
børs: Mere information om SANOFI (I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome) Marketscreener-logo